Advances in the management of squamous cell carcinoma of the head and neck

F1000Prime Reports

Volumn 6, Issue , 2014, Pages

  Machiels, Jean Pascal ^a   Lambrecht, Maarten ^a   Hanin, François Xavier ^a   Duprez, Thierry ^a   Gregoire, Vincent ^a   Schmitz, Sandra ^a   Hamoir, Marc ^a  

^a CLINIQUES UNIVERSITAIRES SAINT LUC   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

CARBOPLATIN; CETUXIMAB; CISPLATIN; CYCLIN DEPENDENT KINASE INHIBITOR 2A; DOCETAXEL; EPIDERMAL GROWTH FACTOR RECEPTOR; FLUOROURACIL; METHOTREXATE; NOTCH1 RECEPTOR; PACLITAXEL; PROTEIN P53;

ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER CONTROL; CANCER PROGNOSIS; CANCER STAGING; CANCER SURVIVAL; CAUSE SPECIFIC SURVIVAL; CHEMORADIOTHERAPY; COMPUTER ASSISTED EMISSION TOMOGRAPHY; COMPUTER ASSISTED TOMOGRAPHY; DIAGNOSTIC ACCURACY; DIFFUSION WEIGHTED IMAGING; DISTANT METASTASIS; GENE DOSAGE; GENE OVEREXPRESSION; HEAD AND NECK SQUAMOUS CELL CARCINOMA; HUMAN; INDUCTION CHEMOTHERAPY; INTENSITY MODULATED RADIATION THERAPY; LASER SURGERY; MICROSURGERY; MINIMALLY INVASIVE SURGERY; MOLECULAR BIOLOGY; MONOTHERAPY; NUCLEAR MAGNETIC RESONANCE; ONCOGENE H RAS; OVERALL SURVIVAL; PERFUSION WEIGHTED IMAGING; PROGRESSION FREE SURVIVAL; RADIOSENSITIVITY; RANDOMIZED CONTROLLED TRIAL (TOPIC); ROBOTICS; SMOKING; SOCIAL INTERACTION; SOMATIC MUTATION; TUMOR RECURRENCE;

EID: 84903145815     PISSN: None     EISSN: 20517599     Source Type: Journal    
DOI: 10.12703/P6-44     Document Type: Article

References (107)

1. International Agency for Research on Cancer. World Health Organisation. Globocan 2012: Estimated cancer incidence, mortality and prevalence worldwide in 2012. [http://globoscan.iarc.fr]
2. Ang KK, Harris J, Wheeler R, Weber R, Rosenthal DI, Nguyen-Tân PF, Westra WH, Chung CH, Jordan RC, Lu C, Kim H, Axelrod R, Silverman CC, Redmond KP, Gillison ML: Human papillomavirus and survival of patients with oropharyngeal cancer. N Eng J Med 2010, 363:24-35.
3. Gillison ML: Human papillomavirus-associated head and neck cancer is a distinct epidemiologic, clinical, and molecular entity. Semin Oncol 2004, 31:744-54.
4. Chaturvedi AK, Anderson WF, Lortet-Tieulent J, Curado MP, Ferlay J, Franceschi S, Rosenberg PS, Bray F, Gillison ML: Worldwide trends in incidence rates for oral cavity and oropharyngeal cancers. J Clin Oncol 2013, 31:4550-9.
5. Chaturvedi AK, Engels EA, Pfeiffer RM, Hernandez BY, Xiao W, Kim E, Jiang B, Goodman MT, Sibug-Saber M, Cozen W, Liu L, Lynch CF, Wentzensen N, Jordan RC, Altekruse S, Anderson WF, Rosenberg PS, Gillison ML: Human papillomavirus and rising oropharyngeal cancer incidence in the United States. J Clin Oncol 2011, 29:4294-301.
6. Ribeiro KB, Levi JE, Pawlita M, Koifman S, Matos E, Eluf-Neto J, Wunsch-Filho V, Curado MP, Shangina O, Zaridze D, Szeszenia-Dabrowska N, Lissowska J, Daudt A, Menezes A, Bencko V, Mates D, Fernandez L, Fabianova E, Gheit T, Tommasino M, Boffetta P, Brennan P, Waterboer T: Low human papillomavirus prevalence in head and neck cancer: results from two large case-control studies in high-incidence regions. Int J Epidemiol 2011, 40:489-502.
7. Grégoire V, Lefebvre J-L, Licitra L, Felip E: Squamous cell carcinoma of the head and neck: EHNS-ESMO-ESTRO Clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol 2010, 21:v184-6.
8. Kalyankrishna S, Grandis JR: Epidermal growth factor biology in head and neck cancer. J Clin Oncol 2006, 24:2666-72.
9. Temam S, Kawaguchi H, El-Naggar AK, Jelinek J, Tang H, Liu DD, Lang W, Issa JP, Lee JJ, Mao L: Epidermal growth factor receptor copy number alterations correlate with poor clinical outcome in patients with head and neck squamous cancer. J Clin Oncol 2007, 25:2164-70.
10. Mrhalova M, Plzak J, Betka J, Kodet R: Epidermal growth factor receptor-its expression and copy numbers of EGFR gene in patients with head and neck squamous cell carcinoma. Neoplasma 2005, 52:338-43.
11. Chung CH, Ely K, McGavran L, Varella-Garcia M, Parker J, Parker N, Jarrett C, Carter J, Murphy BA, Netterville J, Burkey BB, Sinard R, Cmelak A, Levy S, Yarbrough WG, Slebos RJ, Hirsch FR: Increased epidermal growth factor receptor gene copy number is associated with poor progonis in head and neck squamous cell carcinomas. J Clin Oncol 2006, 24:4170-76.
12. Chiang WF, Liu SY, Yen CY, Lin CN, Chen YC, Lin SC, Chang KW: Association of epidermal growth factor receptor (EGFR) gene copy number amplification with neck lymph node metastasis in areca-associated oral carcinoma. Oral Oncol 2008, 44:270-6.
13. Ang KK, Berkey BA, Tu X, Zhang HZ, Katz R, Hammond EH, Fu KK, Milas L: Impact of epidermal growth factor receptor expression on survival and pattern of relapse in patients with advanced head and neck carcinoma. Cancer Res 2002, 62:7350-56.
14. Wheeler S, Siwak DR, Chai R, LaValle C, Seethala RR, Wang L, Cieply K, Sherer C, Joy C, Mills GB, Argiris A, Siegfried JM, Grandis JR, Egloff AM: Tumor epidermal growth factor receptor and EGFR PY1068 are independent prognostic indicators for head and neck squamous cell carcinoma. Clin Cancer Research 2012, 18:2278-89.
15. Rubin Grandis JR, Melhem MF, Gooding WE, Day R, Holst VA, Wagener MM, Drenning SD, Tweardy DJ: Levels of TGFA and EGFR protein in head and neck squamous cell carcinoma and patient survival. J Natl Cancer Inst 1998, 90:824-32.
16. Jedlinski A, Ansell A, Johansson AC, Roberg KJ: EGFR status and EGFR ligand expression influence the treatment response of head and neck cancer cell lines. Oral Pathol Med 2013, 42:26-36.
17. Bentzen SM, Atasoy BM, Daley FM, Dische S, Richman PI, Saunders MI, Trott KR, Wilson GD: Epidermal growth factor receptor expression in pretreatment biopsies from head and neck squamous cell carcinoma as a predictive factor for a benefit from accelerated radiation therapy in a randomized controlled trial. J Clin Oncol 2005, 23:5560-67.
18. Vermorken J, Mesia R, Rivera F, Remenar E, Kawecki A, Rottey S, Erfan J, Zabolotnyy D, Kienzer HR, Cupissol D, Peyrade F, Benasso M, Vynnychenko I, De Raucourt D, Bokemeyer C, Schueler A, Amellal N, Hitt R: Platinum-based chemotherapy plus cetuximab in head and neck cancer. N Eng J Med 2008, 11:1116-27.
19. Bonner JA, Harari PM, Giralt J, Cohen RB, Jones CU, Sur RK, Raben D, Baselga J, Spencer SA, Zhu J, Youssoufian H, Rowinsky EK, Ang KK: Radiotherapy plus cetuximab for locoregionally advanced head and neck cancer: 5-year survival data from a phase 3 randomised trial, and relation between cetuximab-induced rash and survival. Lancet Oncol 2010, 11:21-8.
20. Machiels JP, Subramanian S, Ruzsa A, Repassy G, Lifirenko I, Flygare A, Sørensen P, Nielsen T, Lisby L, Clement P: Zalutumumab in patients with squamous cell carcinoma of the head and neck with recurrent or metastatic disease who failed platinum based chemotherapy, a randomized controlled trial. Lancet Oncol 2011, 12:333-343.
21. Vermorken JB, Herbst RS, Leon X, Amellal N, Baselga J: Overview of the efficacy of cetuximab in recurrent and/or metastatic squamous cell carcinoma of the head and neck in patients who previously failed platinum-based therapies. Cancer 2008, 112:2710-9.
22. Stransky N, Egloff AM, Tward AD, Kostic AD, Cibulskis K, Sivachenko A, Kryukov GV, Lawrence MS, Sougnez C, McKenna A, Shefler E, Ramos AH, Stojanov P, Carter SL, Voet D, Cortés ML, Auclair D, Berger MF, Saksena G, Guiducci C, Onofrio RC, Parkin M, Romkes M, Weissfeld JL, Seethala RR, Wang L, Rangel-Escareño C, Fernandez-Lopez JC, Hidalgo-Miranda A, Melendez-Zajgla J, et al.: The mutational landscape of head and neck squamous cell carcinoma. Science 2011, 333:1157-60.
23. Agrawal N Frederick MJ, Pickering CR, Bettegowda C, Chang K, Li RJ, Fakhry C, Xie TX, Zhang J, Wang J, Zhang N, El-Naggar AK, Jasser SA, Weinstein JN, Treviño L, Drummond JA, Muzny DM, Wu Y, Wood LD, Hruban RH, Westra WH, Koch WM, Califano JA, Gibbs RA, Sidransky D, Vogelstein B, Velculescu VE, Papadopoulos N, Wheeler DA, Kinzler KW, et al.: Exome sequencing of head and neck squamous cell carcinoma reveals inactivating mutations in NOTCH1. Science 2011, 333:1154-57.
24. Hayes DN, Grandis JR, El-Naggar AK: The Cancer Genome Atlas: Integrated analysis of genome alterations in squamous cell carcinoma of the head and neck [abstract]. J Clin Oncol 2013, 31:s6009.
25. Perez-Sayans M, Suarez-Penaranda JM, Gayoso-Diz P, Barros-Angueira F, Gandara-Rey JM, Garcia-Garcia A: p16(INK4a)/CDKN2 expression and its relationship with oral squamous cell carcinoma is our current knowledge enough? Cancer Lett 2009, 306:134-41.
26. Reed AL, Califano J, Cairns P, Westra WH, Jones RM, Koch W, Ahrendt S, Eby Y, Sewell D, Nawroz H, Bartek J, Sidransky D: High frequency of p16 (CDKN2/MTS-1/INK4A) inactivation in head and neck squamous cell carcinoma. Cancer Res 1996, 56:3630-33.
27. Smeets SJ, Brakenhoff RH, Ylstra B, van Wieringen WN, van de Wiel MA, Leemans CR, Braakhuis BJ: Genetic classification of oral and oropharyngeal carcinomas identifies subgroups with a different prognosis. Cell Oncol 2009, 31:291-300.
28. Smeets SJ, Braakhuis BJ, Abbas S, Snijders PJ, Ylstra B, van de Wiel MA, Meijer GA, Leemans CR, Brakenhoff RH: Genome-wide DNA copy number alterations in head and neck squamous cell carcinomas with or without oncogene-expressing human papillomavirus. Oncogene 2006, 25:2558-64.
29. Bova RJ, Quinn DI, Nankervis JS, Cole IE, Sheridan BF, Jensen MJ, Morgan GJ, Hughes CJ, Sutherland RL: Cyclin D1 and p16INK4A expression predict reduced survival in carcinoma of the anterior tongue. Clin Cancer Res 1999, 5:2810-19.
30. Narisawa-Saito M, Kiyono T: Basic mechanisms of high risk human papillomavirus -induced carcinogenesis: Roles of E6 and E7 proteins. Cancer Sci 2007, 98:1505-11.
31. Slebos RJ, Yi Y, Ely K, Carter J, Evjen A, Zhang X, Shyr Y, Murphy BM, Cmelak AJ, Burkey BB, Netterville JL, Levy S, Yarbrough WG, Chung CH: Gene expression differences associated with human papillomavirus status in head and neck squamous cell carcinoma. Clin Cancer Res 2006, 12:701-9.
32. Nichols AC, Chan-Seng-Yue M, Yoo J, Xu W, Dhaliwal S, Basmaji J, Szeto CC, Dowthwaite S, Todorovic B, Starmans MH, Lambin P, Palma DA, Fung K, Franklin JH, Wehrli B, Kwan K, Koropatnick J, Mymryk JS, Boutros P, Barrett JW: A pilot study comparing HPV-positive and HPV-negative head and neck squamous cell carcinomas by whole exome sequencing. ISRN Oncol 2012, 2012:809370.
33. Lechner M, Frampton GM, Fenton T, Feber A, Palmer G, Jay A, Pillay N, Forster M, Cronin MT, Lipson D, Miller VA, Brennan TA, Henderson S, Vaz F, O'Flynn P, Kalavrezos N, Yelensky R, Beck S, Stephens PJ, Boshoff C: Targeted next-generation sequencing of head and neck squamous cell carcinoma identifies novel genetic alterations in HPV+ and HPV- tumors. Genome Med 2013, 5:49.
34. Weinberger PM, Yu Z, Kountourakis P, Sasaki C, Haffty BG, Kowalski D, Merkley MA, Rimm DL, Camp RL, Psyrri A: Defining molecular phenotypes of human papillomavirus-associated oropharyngeal squamous cell carcinoma: validation of threeclass hypothesis. Otolaryngol Head Neck Surg 2009, 141:382-9.
35. Smith EM, Rubenstein LM, Hoffman H, Haugen TH, Turek LP: Human papillomavirus, p16 and p53 expression associated with survival of head and neck cancer. Infect Agent Cancer 2010, 5:4.
36. Gillison ML, Harris J, Westra W, Chung C, Jordan R, Rosenthal D, Nguyen-Tan P, Spanos WJ, Redmond KP, Ang K and Radiation Therapy Oncology Group: Survival outcomes by tumor human papillomavirus (HPV) status in stage III-IV oropharyngeal cancer (OPC) in RTOG 0129 [abstract]. J Clin Oncol 2009, 27:s6003.
37. Schoder H, Yeung HW, Gonen M, Kraus D, Larson SM: Head and neck cancer: clinical usefulness and accuracy of PET/CT image fusion. Radiology 2004, 231:65-72.
38. Wong WL, Ross P, Corcoran M: Evidence-based guideline recommendations on the use of positron emission tomography imaging in head and neck cancer from Ontario and guidelines in general-some observations. Clin Oncol (R Coll Radiol) 2013, 25:242-5.
39. Wong WL, Sonoda LI, Gharpurhy A, Gollub F, Wellsted D, Goodchild K, Lemon C, Farrell R, Saunders M: 18F-fluorodeoxyglucose positron emission tomography/computed tomography in the assessment of occult primary head and neck cancers-an audit and review of published studies. Clin Oncol (R Coll Radiol) 2012, 24:190-5.
40. NCCN: National Comprehensive Cancer Network Clinical Practice guidelines in Oncology: Head and Neck cancers. Version 2.2013; 2014. [http:// oralcancerfoundation.org/treatment/pdf/head-and-neck.pdf]
41. SNM: Society of Nuclear Medicine Oncology practice Guidelines Summary; 2013. [http://www.snm.org/docs/PET-PROS/OncologyPracticeGuidelineSummary.pdf]
42. Escott EJ: Role of positron emission tomography/computed tomography (PET/CT) in head and neck cancer. Radiol Clin North Am 2013, 51:881-93.
43. Gupta T, Master Z, Kannan S, Agarwal JP, Ghsoh-Laskar S, Rangarajan V, Murthy V, Budrukkar A: Diagnostic performance of post-treatment FDG PET or FDG PET/CT imaging in head and neck cancer: a systematic review and meta-analysis. Eur J Nucl Med Mol Imaging 2011, 38:2083-95.
44. Porceddu SV, Pryor DI, Burmeister E, Burmeister BH, Poulsen MG, Foote MC, Panizza B, Coman S, McFarlane D, Coman W: Results of a prospective study of positron emission tomography-directed management of residual nodal abnormalities in node-positive head and neck cancer after definitive radiotherapy with or without systemic therapy. Head Neck 2011, 33:1675-82.
45. Inohara H, Enomoto K, Tomiyama Y, Higuchi I, Inoue T, Hatazawa J: The role of CT and (1)(8)F-FDG PET in managing the neck in node-positive head and neck cancer after chemoradiotherapy. Acta Otolaryngol 2009, 129:893-9.
46. Grosu AL, Souvatzoglou M, Roper B, Dobritz M, Wiedenmann N, Jacob V, Wester HJ, Reischl G, Machulla HJ, Schwaiger M, Molls M, Piert M: Hypoxia imaging with FAZA-PET and theoretical considerations with regard to dose painting for individualization of radiotherapy in patients with head and neck cancer. Int J Radiat Oncol Biol Phys 2007, 69:541-51.
47. Lelandais B, Gardin I, Mouchard L, Vera P, Ruan S: Segmentation of biological target volumes on multi-tracer PET images based on information fusion for achieving dose painting in radiotherapy. Med Image Comput Comput Assist Interv 2012, 15:545-52.
48. Gregoire V, Jeraj R, Lee JA, O'Sullivan B: Radiotherapy for head and neck tumours in 2012 and beyond: conformal, tailored, and adaptive? Lancet Oncol 2012, 13:e292-300.
49. Petrou M, Mukherji SK: Extracranial head and neck neoplasm: role of imaging. Cancer Treat Res 2008, 143:93-117.
50. Daisne JF, Duprez T, Weynand B, Lonneux M, Hamoir M, Reychler H, Grégoire V: Tumor volume in pharyngolaryngeal squamous cell carcinoma: comparison at CT, MR imaging, and FDG PET and validation with surgical specimen. Radiology 2004, 233:93-100.
51. Curtin HD, Ishwaran H, Dalley RW, Caudry DJ, McNeil BJ: Comparison of CT and MR imaging in staging of neck metastases. Radiology 1998, 207:123-30.
52. King AD, Tse GM, Ahuja AT, Yuen EH, Vlantis A, To EW, van Hasselt AC: Necrosis in metastatic neck nodes: diagnostic accuracy of CT, MR imaging, and US. Radiology 2004, 230:720-26.
53. Schmidt GP, Kramer H, Reiser MF, Glaser C: Whole-body magnetic resonance imaging and positron emission tomography-computed tomography in oncology. Top Magn reson Imaging 2007, 18:193-202.
54. Thoeny HC, De Keyzer F, King AD: Diffusion-weighted MR imaging in the head and the neck. Radiology 2012, 263:19-32.
55. Vandecaveye V, De Keyzer F, Vander Poorten V, dirix P, Verbeken E, Nuyts S, Hermans R: Head and neck squamous cell carcinoma: value of diffusion-weighted MR imaging for nodal staging. Radiology 2009, 251:134-45.
56. Shukla-Dave A, Lee NY, Jansen JFA, Thaler HT, Stambuk HE, Fury MG, Patel SG, Moreira AL, Sherman E, Karimi S, Wang Y, Kraus D, Shah JP, Pfister DG, Koutcher JA: Dynamic contrast-enhanced MRI as predictor of outcome in HNSCC patients with nodal metastases. Int J Radiation Oncology Biol Phys 2012, 82:1837-44.
57. Varoquaux A, Rager O, Lövblad K-O, Masterson K, Dulguerov P, Ratib O, Becker CD, Becker M: Functional imaging of HNSCC with diffusion-weighted MRI and FDG PET/CT: quantitative analysis of ADC and SUV. Eur J Nucl Med Mol Imaging 2014, 41:462-75.
58. Sumi M, Nakamura T: Head and neck tumors: combined MRI assessment based on IVIM and TIC analyses for the differentiation of tumors of different histological types. Eur Radiol 2014, 24:223-31.
59. Veldeman L, Madani I, Hulstaert F, De Meerleer G, Mareel M, De Neve W: Evidence behind use of intensity-modulated radiotherapy: a systematic review of comparative clinical studies. Lancet Oncol 2008, 9:367-75.
60. Nutting CM, Morden JP, Harrington KJ, Urbano TG, Bhide SA, Clark C, Miles EA, Miah AB, Newbold K, Tanay M, Adab F, Jefferies SJ, Scrase C, Yap BK, A'Hern RP, Sydenham MA, Emson M, Hall E; PARSPORT trial management group: Parotid-sparing intensity modulated versus conventional radiotherapy in head and neck cancer (PARSPORT): a phase 3 multicentre randomised controlled trial. Lancet Oncol 2011, 12:127-36.
61. Kam MK, Leung SF, Zee B, Chau RM, Suen JJ, Mo F, Lai M, Ho R, Cheung KY, Yu BK, Chiu SK, Choi PH, Teo PM, Kwan WH, Chan AT: Prospective randomized study of intensity-modulated radiotherapy on salivary gland function in early-stage nasopharyngeal carcinoma patients. J Clin Oncol 2007, 25:4873-9.
62. Pow EH, Kwong DL, McMillan AS, Wong MC, Sham JS, Leung LH, Leung WK: Xerostomia and quality of life after intensity-modulated radiotherapy vs. conventional radiotherapy for early-stage nasopharyngeal carcinoma: initial report on a randomized controlled clinical trial. Int J Radiat Oncol Biol Phys 2006, 66:981-91.
63. Feng FY, Kim HM, Lyden TH, Haxer MJ, Feng M, Worden FP, Chepeha DB, Eisbruch A: Intensity-modulated radiotherapy of head and neck cancer aiming to reduce dysphagia: early dose-effect relationships for the swallowing structures. Int J Radiat Oncol Biol Phys 2007, 68:1289-98.
64. Eisbruch A, Kim HM, Feng FY, Lyden TH, Haxer MJ, Feng M, Worden FP, Bradford CR, Prince ME, Moyer JS, Wolf GT, Chepeha DB, Ten Haken RK: Chemo-IMRT of oropharyngeal cancer aiming to reduce dysphagia: swallowing organs late complication probabilities and dosimetric correlates. Int J Radiat Oncol Biol Phys 2011, 81:e93-9.
65. Nuyts S, Lambrecht M, Duprez F, Daisne JF, Van Gestel D, Van den Weyngaert D, Platteaux N, Geussens Y, Voordeckers M, Madani I, De Neve W: Reduction of the dose to the elective neck in head and neck squamous cell carcinoma, a randomized clinical trial using intensity modulated radiotherapy (IMRT). Dosimetrical analysis and effect on acute toxicity. Radiother Oncol 2013, 109:323-9.
66. Mendenhall WM, Amdur RJ, Palta JR: Intensity-modulated radiotherapy in the standard management of head and neck cancer: promises and pitfalls. J Clin Oncol 2006, 24:2618-23.
67. Feng M and Eisbruch A: Future issues in highly conformal radiotherapy for head and neck cancer. J Clin Oncol 2007, 25:1009-13.
68. Chao KS, Wippold FJ, Ozyigit G, Tran BN, Dempsey JF: Determination and delineation of nodal target volumes for head-and-neck cancer based on patterns of failure in patients receiving definitive and postoperative IMRT. Int J Radiat Oncol Biol Phys 2002, 53:1174-84.
69. Eisbruch A, Foote RL, O'Sullivan B, Beitler JJ, Vikram B: Intensity-modulated radiation therapy for head and neck cancer: emphasis on the selection and delineation of the targets. Semin Radiat Oncol 2002, 12:238-49.
70. Gregoire V, Ang K, Budach W, Grau C, Hamoir M, Langendijk JA, Lee A, Le QT, Maingon P, Nutting C, O'Sullivan B, Porceddu SV, Lengele B: Delineation of the neck node levels for head and neck tumors: A 2013 update. DAHANCA, EORTC, HKNPCSG, NCIC CTG, NCRI, RTOG, TROG consensus guidelines. Radiother Oncol 2013, 110:172-81.
71. Beadle BM, Liao KP, Elting LS, Buchholz TA, Ang KK, Garden AS, Guadagnolo BA: Improved survival using intensity-modulated radiation therapy in head and neck cancers: A SEER-Medicare analysis. Cancer 2014, 120:702-10.
72. Bentzen SM and Gregoire V: Molecular imaging-based dose painting: a novel paradigm for radiation therapy prescription. Semin Radiat Oncol 2011, 21:101-10.
73. Lambrecht M, Van Herck H, de Keyzer F, Vandecaveye V, Slagmolen P, Suetens P, Hermans R, Nuyts S: Redefining the target early during treatment. Can we visualize regional differences within the target volume using sequential diffusion weighted MRI? Radiother Oncol 2013, 110:329-34.
74. Withers HR: Biologic basis for altered fractionation schemes. Cancer 1985, 55:2086-95.
75. Bourhis J, Overgaard J, Audry H, Ang KK, Saunders M, Bernier J, Horiot JC, Le Maître A, Pajak TF, Poulsen MG, O'Sullivan B, Dobrowsky W, Hliniak A, Skladowski K, Hay JH, Pinto LH, Fallai C, Fu KK, Sylvester R, Pignon JP: Hyperfractionated or accelerated radiotherapy in head and neck cancer: a meta-analysis. Lancet 2006, 368:843-54.
76. Pignon JP, le Maitre A, Maillard E, Bourhis: Meta-analysis of chemotherapy in head and neck cancer (MACH-NC): an update on 93 randomised trials and 17,346 patients. Radiother Oncol 2009, 92:4-14.
77. Blanchard P, Baujat B, Holostenco V, Bourredjem A, Baey C, Bourhis J, Pignon JP; MACH-CH Collaborative group: Meta-analysis of chemotherapy in head and neck cancer (MACH-NC): a comprehensive analysis by tumour site. Radiother Oncol 2011, 100: 33-40.
78. Hitt R, Grau JJ, López-Pousa A, Berrocal A, García- Girón C, Irigoyen A, Sastre J, Martínez-Trufero J, Brandariz Castelo JA, Verger E, Cruz-Hernández JJ; Spanish Head and Neck Cancer Cooperative Group (TTCC): A randomized phase III trial comparing induction chemotherapy followed by chemoradiotherapy versus chemoradiotherapy alone as treatment of unresectable head and neck cancer. Ann Oncol 2014, 25:216-25.
79. Cohen EEW, Karrison T, Kocherginsky M, Huang CH, Agulnik M, Mittal BB, Yunus F, Samant S, Brockstein B, Raez LE, Mehra R, Kumar P, Ondrey FG, Seiwert TY, Villaflor VM, Haraf DJ and Vokes EE: DeCIDE: a phase III randomized trial of docetaxel (D), cisplatin (P), 5-fluorouracil (F)(TPF) induction chemotherapy (IC) in patients with N2/N3 locally advanced squamous cell carcinoma of the head and neck (SCCHN) [abstract]. J Clin Oncol 2012, 30:s5500.
80. Haddad R, O'Neill A, Rabinowits G, Tishler R, Khuri F, Adkins D, Clark J, Sarlis N, Lorch J, Beitler JJ, Limaye S, Riley S, Posner M: Induction chemotherapy followed by concurrent chemoradiotherapy (sequential chemoradiotherapy) versus concurrent chemoradiotherapy alone in locally advanced head and neck cancer (PARADIGM): a randomised phase 3 trial. Lancet Oncol 2013, 14:257-64.
81. Bonner JA, Harari PM, Giralt J, Azarnia N, Shin DM, Cohen RB, Jones CU, Sur R, Raben D, Jassem J, Ove R, Kies MS, Baselga J, Youssoufian H, Amellal N, Rowinsky EK, Ang KK: Radiotherapy plus cetuximab for squamous-cell carcinoma of the head and neck. N Engl J Med 2006, 354:567-78.
82. Bourhis J, Sire C, Graff P, Grégoire V, Maingon P, Calais G, Gery B, Martin L, Alfonsi M, Desprez P, Pignon T, Bardet E, Rives M, Geoffrois L, Daly-Schveitzer N, Sen S, Tuchais C, Dupuis O, Guerif S, Lapeyre M, Favrel V, Hamoir M, Lusinchi A, Temam S, Pinna A, Tao YG, Blanchard P, Aupérin A: Concomitant chemoradiotherapy versus acceleration of radiotherapy with or without concomitant chemotherapy in locally advanced head and neck carcinoma (GORTEC 99-02): an open-label phase 3 randomised trial. Lancet Oncol 2012, 13:145-53.
83. Ang KK, Zhang QE, Rosenthal DI, Nguyen-Tan P, Sherman EJ, Weber RS, Galvin JM, Schwartz DL, El-Naggar AK, Gillison ML, Jordan R, List MA, Konski AA, Thorstad WL, Trotti A, Beitler JJ, Garden AS, Spanos WJ, Yom SS and Axelrod RS: A randomized phase III trial (RTOG 0522) of concurrent accelerated radiation plus cisplain with our without cetuximab for stage III-IV head and neck squamous cell carcinoma. [abstract]. J Clin Oncol 2011, 29:s5500.
84. Martins RG, Parvathaneni U, Bauman JE, Sharma AK, Raez LE, Papagikos MA, Yunus F, Kurland BF, Eaton KD, Liao JJ, Mendez E, Futran N, Wang DX, Chai X, Wallace SG, Austin M, Schmidt R, Hayes DN: Cisplatin and radiotherapy with or without erlotinib in locally advanced squamous cell carcinoma of the head and neck: a randomized phase II trial. J Clin Oncol 2013, 31:1415-21.
85. Ferlito A, Takes RP, Silver CE, Strojan P, Haigentz M Jr, Robbins KT, Genden EM, Hartl DM, Shaha AR, Rinaldo A, Suárez C, Olsen KD: The changing role of surgery in the current era of head and neck oncology. Eur Arch Otorhinolaryngol 2013, 270:1971-3.
86. The Department of Veterans Affairs Laryngeal Cancer Study Group: Induction Chemotherapy plus Radiation Compared with Surgery plus Radiation in Patients with Advanced Laryngeal Cancer. N Engl J Med 1991, 324:1685-90.
87. Forastiere AA, Goepfert H, Maor M, Pajak TF, Weber R, Morrison W, Glisson B, Trotti A, Ridge JA, Chao C, Peters G, Lee DJ, Leaf A, Ensley J, Cooper J: Concurrent chemotherapy and radiotherapy for organ preservation in advanced laryngeal cancer. N Engl J Med 2003, 349:2091-8.
88. Hartl DM, Brasnu DF, Shah JP, Hinni ML, Takes RP, Olsen KD, Kowalski LP, Rodrigo JP, Strojan P, Wolf GT, Rinaldo A, Suárez C, Mendenhall WM, Paleri V, Forastiere AA, Werner JA, Ferlito A: Is open surgery for head and neck cancers truly declining? Eur Arch Otorhinolaryngol 2013, 270:2793-802.
89. Grégoire V, Hamoir M, Rosier JF, Counoy H, Eeckhoudt L, Neymark N, Scalliet P: Cost-minimization analysis of treatment options for T1N0 glottic squamous cell carcinoma: comparison between external radiotherapy, laser microsurgery and partial laryngectomy. Radiother Oncol 1999, 53:1-13.
90. van Loon Y, Sjögren EV, Langeveld TP, Baatenburg de Jong RJ, Schoones JW, van Rossum MA: Functional outcomes after radiotherapy or laser surgery in early glottic carcinoma: a systematic review. Head Neck 2012, 34:1179-89.
91. Canis M, Ihler F, Martin A, Wolff HA, Matthias C, Steiner W: Organ preservation in T4a laryngeal cancer: is transoral laser microsurgery an option? Eur Arch Otorhinolaryngol 2013, 270:2719-27.
92. Canis M, Ihler F, Martin A, Wolff HA, Matthias C, Steiner W: Results of 226 patients with T3 laryngeal carcinoma after treatment with transoral laser microsurgery. Head Neck 2013, 36:652-9.
93. Genden EM, O'Malley BW Jr, Weinstein GS, Stucken CL, Selber JC, Rinaldo A, Hockstein NG, Ozer E, Mallet Y, Satava RM, Moore EJ, Silver CE, Ferlito A: Transoral robotic surgery: role in the management of upper aerodigestive tract tumors. Head Neck 2012, 34:886-93.
94. Vergez S, Lallemant B, Ceruse P, Moriniere S, Aubry K, De Mones E, Benlyazid A, Mallet Y: Initial multi-institutional experience with transoral robotic surgery. Otolaryngol Head Neck Surg 2012, 147:475-81.
95. Shah JP: Patterns of cervical lymph node metastasis from squamous carcinomas of the upper aerodigestive tract. Am J Surg 1990, 160:405-9.
96. Hamoir M, Fievez J, Schmitz S, Velasco D, Lengele B: Extended voice-sparing surgery in selected pyriform sinus carcinoma: techniques and outcomes. Head Neck 2013, 35:1482-9.
97. Schmitz, Machiels JP, Weynand B, Grégoire V, Hamoir M: Results of selective neck dissection in the primary management of head and neck squamous cell carcinoma. Eur Arch Otorhinolaryngol 2009, 266:437-43.
98. Robbins KT, Ferlito A, Shah JP, Hamoir M, Takes RP, Strojan P, Khafif A, Silver CE, Rinaldo A, Medina JE: The evolving role of selective neck dissection for head and neck squamous cell carcinoma. Eur Arch Otorhinolaryngol 2013, 270:1195-202.
99. Brizel DM, Prosnitz RG, Hunter S, Fisher SR, Clough RL, Downey MA, Scher RL: Necessity for adjuvant neck dissection in setting of concurrent chemoradiation for advanced head-and-neck cancer. Int J Radiat Oncol Biol Phys 2004, 58:1418-23.
100. Argiris A, Stenson KM, Brockstein BE, Mittal BB, Pelzer H, Kies MS, Jayaram P, Portugal L, Wenig BL, Rosen FR, Haraf DJ, Vokes EE: Neck dissection in the combined-modality therapy of patients with locoregionally advanced head and neck cancer. Head Neck 2004, 26:447-55.
101. Hamoir M, Ferlito A, Schmitz S, Hanin FX, Thariat J, Weynand B, Machiels JP, Grégoire V, Robbins KT, Silver CE, Strojan P, Rinaldo A, Corry J, Takes RP: The role of neck dissection in the setting of chemoradiation therapy for head and neck squamous cell carcinoma with advanced neck disease. Oral Oncol 2012, 48:203-10.
102. Robbins KT, Wong FSH, Kumar P, Hartsell WF, Vieira F, Mullins B, Niell HB: Efficacy of targeted chemoradiation and planned selective neck dissection to control bulky nodal disease in advanced head and neck cancer. Arch Otolaryngol Head Neck Surg 1999, 125:670-5.
103. Stenson KM, Huo D, Blair E, Cohen EE, Argiris A, Haraf DJ, Vokes EE: Planned post-chemoradiation neck dissection: significance of radiation dose. Laryngoscope 2006, 116:33-6.
104. Robbins JT, Doweck I, Samant S, Vieira F: Effectiveness of superselective and selective neck dissection for advanced nodal metastases after chemoradiation. Arch Otolaryngol Head Neck Surg 2005, 131:965-9.
105. Mukhija V, Gupta S, Jacobson AS, Anderson Eloy J, Genden EM: Selective neck dissection following adjuvant therapy for advanced head and neck cancer. Head Neck 2009, 31:183-8.
106. Dhiwakar M, Robbins KT, Vieira F, Rao K, Malone J: Selective neck dissection as an early salvage intervention for clinically persistent nodal disease following chemoradiation. Head Neck 2012, 34:188-93.
107. Schmitz S, Ang KK, Vermorken J, Haddad R, Suarez C, Wolf GT, Hamoir M, Machiels JP: Targeted therapies for squamous cell carcinoma of the head and neck : current knowledge and future directions. Cancer Treat Rev 2014, 40:390-404.